Apelin-13 (TFA)

Apelin-13 TFA is an endogenous ligand for the G-protein coupled receptor angiotensin II protein J (APJ), activating this G protein-coupled receptor with an EC 50 value of 0.37 nM. Apelin-13 TFA has vasodilatory and antihypertensive effects. Apelin-13 TFA also can be used for researching type 2 diabetes and metabolic syndrome[1][2][3].

Product Specifications

UNSPSC

12352209

Target

Apelin Receptor (APJ)

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Metabolic Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/apelin-13-tfa.html

Purity

98.98

Solubility

DMSO : ≥ 100 mg/mL|H2O : 50 mg/mL (ultrasonic)

Smiles

O=C(O)[C@H](CC1=CC=CC=C1)NC([C@H]2N(C([C@H](CCSC)NC([C@H]3N(C(CNC([C@H](CCCCN)NC([C@H](CC4=CNC=N4)NC([C@H](CO)NC([C@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H]5N(C([C@H](CCCNC(N)=N)NC([C@H](CCC(N)=O)N)=O)=O)CCC5)=O)=O)=O)=O)=O)=O)=O)CCC3)=O)=O)CCC2)=O.OC(C(F)(F)F)=O

Molecular Formula

C71H112F3N23O18S

Molecular Weight

1664.85

References & Citations

[1]Tatemoto, K., et al. Isolation and characterizaton of a novel endogenous peptide ligand for the human APJ receptor. Biochemical and Biophysical Research Communications 251, 471-476 (1998) .|[2]Li M, et al. Apelin 13 ameliorates metabolic and cardiovascular disorders in a rat model of type 2 diabetes with a high fat diet. Mol Med Rep. 2018 Dec;18 (6) :5784-5790.|[3]Yamaleyeva LM, et al. Apelin-13 in blood pressure regulation and cardiovascular disease. Curr Opin Nephrol Hypertens. 2016 Sep;25 (5) :396-403.|[4]Wang Y, et al. Apelin-13 regulates electrical activity in the globus pallidus and induces postural changes in rats. Neural Regen Res. 2021 Nov;16 (11) :2264-2268.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Scientific Category

Peptides

Clinical Information

Phase 1

Citation 01

Free Radic Res. 2024 Dec 28:1-14.|Int J Nanomedicine. 2024 Sep 7:19:9175-9193.|Ren Fail. 2025 Dec;47 (1) :2480243.|SSRN. 2025 Oct 9.|Stem Cells Int. 2022 Mar 21;2022:3742678.|Ann Transl Med. 2021 Apr;9 (8) :627.|Biochim Biophys Acta Mol Basis Dis. 2024 Mar 19;1870 (4) :167125.|Microsc Res Tech. 2024 Jun;87 (6) :1348-1358.|Signal Transduct Target Ther. 2021 Dec 16;6 (1) :427.